Image may be NSFW.
Clik here to view.
Analysts expect Ocular Therapeutix, Inc. (NASDAQ:OCUL) to report earnings of ($0.18) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Ocular Therapeutix’s earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.15). Ocular Therapeutix reported earnings per share of ($0.47) in the same quarter last year, which would suggest a positive year over year growth rate of 61.7%. The company is scheduled to report its next quarterly earnings report on Thursday, March 11th.
On average, analysts expect that Ocular Therapeutix will report full-year earnings of ($1.31) per share for the current fiscal year, with EPS estimates ranging from ($1.39) to ($1.20). For the next financial year, analysts forecast that the firm will post earnings of ($0.46) per share, with EPS estimates ranging from ($0.63) to ($0.23). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Ocular Therapeutix.
Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02. Ocular Therapeutix had a negative net margin of 780.19% and a negative return on equity of 14,065.71%. The company had revenue of $5.88 million for the quarter, compared to the consensus estimate of $5.85 million.
A number of analysts recently weighed in on the stock. Raymond James upped their target price on shares of Ocular Therapeutix from $15.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 13th. Zacks Investment Research raised shares of Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research note on Saturday, December 5th. Piper Sandler upped their target price on shares of Ocular Therapeutix from $16.00 to $28.00 in a research note on Monday, December 21st. HC Wainwright lowered shares of Ocular Therapeutix from a “buy” rating to a “neutral” rating in a research report on Monday, December 28th. Finally, JMP Securities boosted their price target on shares of Ocular Therapeutix from $20.00 to $30.00 in a research report on Wednesday, December 30th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Ocular Therapeutix has an average rating of “Buy” and a consensus target price of $21.86.
NASDAQ:OCUL opened at $18.15 on Tuesday. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -10.14 and a beta of 2.29. The firm’s 50-day moving average is $20.90 and its 200-day moving average is $13.15. Ocular Therapeutix has a 52-week low of $3.78 and a 52-week high of $24.30. The company has a debt-to-equity ratio of 8.86, a quick ratio of 3.53 and a current ratio of 3.58.
A number of large investors have recently added to or reduced their stakes in OCUL. Bank of New York Mellon Corp boosted its position in Ocular Therapeutix by 36.8% in the second quarter. Bank of New York Mellon Corp now owns 168,667 shares of the biopharmaceutical company’s stock valued at $1,406,000 after buying an additional 45,335 shares in the last quarter. Bank of Montreal Can raised its position in Ocular Therapeutix by 633.2% in the 2nd quarter. Bank of Montreal Can now owns 4,744 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 4,097 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Ocular Therapeutix by 43.2% in the 2nd quarter. Vanguard Group Inc. now owns 3,007,159 shares of the biopharmaceutical company’s stock valued at $25,050,000 after buying an additional 907,320 shares during the period. Bank of America Corp DE raised its position in shares of Ocular Therapeutix by 516.3% during the second quarter. Bank of America Corp DE now owns 85,579 shares of the biopharmaceutical company’s stock worth $712,000 after acquiring an additional 71,692 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of Ocular Therapeutix during the second quarter worth $610,000. Hedge funds and other institutional investors own 52.45% of the company’s stock.
About Ocular Therapeutix
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.
Read More: How does equity income fit into an investing strategy?
Get a free copy of the Zacks research report on Ocular Therapeutix (OCUL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Image may be NSFW.
Clik here to view.